The Scientist magazine today picked up
on the item on the California Stem Cell Report that said that Asterias
Therapeutics would receive $14.3 million to continue the human
embryonic stem cell trial that was abandoned by Geron.
The Scientist article by Jef Akst was headlined,
“Geron
hESC Trial to Resume? Nearly
three years after Geron shuttered its stem cell program, BioTime
receives funding to relaunch a Phase 1 trial for spinal cord injury.”
The brief piece largely cited
information contained in our May 22 item. Akst also said that
Asterias, a subsidiary of Biotime, and the California stem cell
agency, which is expected to provide the cash, declined to comment.
Asterias also has reported successful results from the first phase of the trial.
No comments:
Post a Comment